头孢他洛酯-他唑巴坦和其他抗菌药物对洋葱伯克霍尔德菌复合体和脆弱拟杆菌的活性。
Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli.
机构信息
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
出版信息
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00766-17. Print 2017 Sep.
Abstract
We tested the activities of ceftolozane-tazobactam and 13 other antimicrobial agents against 221 strains of complex and Most strains (82%) were cultured from persons with cystic fibrosis, and most (85%) were recovered since 2011. The ceftolozane-tazobactam MIC was ≤8 μg/ml for 77% of the strains. However, the MIC range was broad (≤0.5 to >64 μg/ml; MIC, 2/32 μg/ml). Significant differences in susceptibility to some antimicrobial agents were observed between species.
摘要
我们测试了头孢他啶-他唑巴坦和其他 13 种抗菌药物对 221 株复杂菌株的活性，这些菌株大多数（82%）是从囊性纤维化患者中培养出来的，并且大多数（85%）是自 2011 年以来恢复的。头孢他啶-他唑巴坦的 MIC 对 77%的菌株为≤8μg/ml。然而，MIC 范围很广（≤0.5 至>64μg/ml；MIC，2/32μg/ml）。一些抗菌药物的敏感性在不同种属之间存在显著差异。
相似文献
1
Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli.头孢他洛酯-他唑巴坦和其他抗菌药物对洋葱伯克霍尔德菌复合体和脆弱拟杆菌的活性。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00766-17. Print 2017 Sep.
2
In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.七种β-内酰胺类药物（包括头孢洛扎/他唑巴坦和头孢他啶/阿维巴坦）对从囊性纤维化患者中分离出的洋葱伯克霍尔德菌复合体、唐菖蒲伯克霍尔德菌及其他非发酵革兰氏阴性杆菌的体外活性。
J Antimicrob Chemother. 2019 Feb 1;74(2):525-528. doi: 10.1093/jac/dky423.
3
"Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Complex and Cystic Fibrosis Isolates.“切换伙伴”：哌拉西林-他唑巴坦对多药耐药复杂菌和囊性纤维化分离株具有强大的联合作用。
J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00181-19. Print 2019 Aug.
4
Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.囊性纤维化患者分离的洋葱伯克霍尔德菌复合体对头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦的敏感性。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00590-18. Print 2018 Sep.
5
Major Aspects of Burkholderia gladioli and Burkholderia cepacia Infections in Children.类洋葱伯克霍尔德菌和洋葱伯克霍尔德菌感染儿童的主要方面。
Pediatr Infect Dis J. 2020 May;39(5):374-378. doi: 10.1097/INF.0000000000002587.
6
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).针对2011 - 12年在欧洲医院分离出的具有不同耐药模式的铜绿假单胞菌和肠杆菌科细菌测试头孢洛扎/他唑巴坦的抗菌活性。
J Antimicrob Chemother. 2014 Oct;69(10):2713-22. doi: 10.1093/jac/dku184. Epub 2014 Jun 10.
7
Comment on: In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.评论：七种β-内酰胺类药物（包括头孢洛扎/他唑巴坦和头孢他啶/阿维巴坦）对从囊性纤维化患者中分离出的洋葱伯克霍尔德菌复合体、唐菖蒲伯克霍尔德菌及其他非发酵革兰氏阴性杆菌的体外活性
J Antimicrob Chemother. 2019 Oct 1;74(10):3122-3123. doi: 10.1093/jac/dkz307.
8
Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.从囊性纤维化患者中分离出的洋葱伯克霍尔德菌复合体的药敏性及协同性研究。
Antimicrob Agents Chemother. 2007 Mar;51(3):1085-8. doi: 10.1128/AAC.00954-06. Epub 2006 Dec 11.
9
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.在体外研究头孢洛扎/他唑巴坦对西班牙医疗机构分离的铜绿假单胞菌和肠杆菌科临床分离株的活性：CENIT 研究结果。
Int J Antimicrob Agents. 2015 Nov;46(5):502-10. doi: 10.1016/j.ijantimicag.2015.07.004. Epub 2015 Aug 10.
10
In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.体外研究头孢洛扎/他唑巴坦对成人囊性纤维化铜绿假单胞菌和其他非发酵革兰阴性菌的抗菌活性。
J Glob Antimicrob Resist. 2018 Sep;14:224-227. doi: 10.1016/j.jgar.2018.03.002. Epub 2018 Mar 17.
引用本文的文献
1
In vitro susceptibility of to ceftazidime-avibactam: A systematic review.对头孢他啶-阿维巴坦的体外敏感性：一项系统评价。
New Microbes New Infect. 2025 May 28;66:101601. doi: 10.1016/j.nmni.2025.101601. eCollection 2025 Aug.
2
Satisfactory In Vitro Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant But Not against Isolates.头孢洛扎他唑巴坦对碳青霉烯类耐药但对非耐药分离株具有满意的体外活性。
Medicina (Kaunas). 2023 Mar 7;59(3):518. doi: 10.3390/medicina59030518.
3
Nosocomial Pneumonia in the Era of Multidrug-Resistance: Updates in Diagnosis and Management.多重耐药时代的医院获得性肺炎：诊断与管理的进展
Microorganisms. 2021 Mar 5;9(3):534. doi: 10.3390/microorganisms9030534.
4
A rapid screening method for the detection of specialised metabolites from bacteria: Induction and suppression of metabolites from Burkholderia species.一种用于检测细菌特殊代谢产物的快速筛选方法：伯克霍尔德氏菌属代谢产物的诱导与抑制
J Microbiol Methods. 2020 Sep 14;178:106057. doi: 10.1016/j.mimet.2020.106057.
5
Complex Bacteria: a Feared Contamination Risk in Water-Based Pharmaceutical Products.复杂细菌：水性药品中令人担忧的污染风险
Clin Microbiol Rev. 2020 Apr 15;33(3). doi: 10.1128/CMR.00139-19. Print 2020 Jun 17.
6
In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates.头孢洛扎/他唑巴坦对非发酵革兰阴性囊性纤维化分离株的体外活性
Open Forum Infect Dis. 2018 Jul 2;5(7):ofy158. doi: 10.1093/ofid/ofy158. eCollection 2018 Jul.
7
Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.囊性纤维化患者分离的洋葱伯克霍尔德菌复合体对头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦的敏感性。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00590-18. Print 2018 Sep.
8
Susceptibility of Ceftolozane-Tazobactam against Burkholderia pseudomallei.头孢洛扎-他唑巴坦对类鼻疽伯克霍尔德菌的敏感性。
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00103-18. Print 2018 May.
9
Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.治疗医院获得性感染的耐多药和广泛耐药非发酵革兰阴性菌：迈向“分子靶向”治疗的危险之旅。
Expert Rev Anti Infect Ther. 2018 Feb;16(2):89-110. doi: 10.1080/14787210.2018.1425139. Epub 2018 Jan 16.
本文引用的文献
1
Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.头孢他啶阿维巴坦对从囊性纤维化患者中分离出的耐多药非发酵革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02688-16. Print 2017 Apr.
2
Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.头孢洛扎/他唑巴坦、头孢他啶、美罗培南和哌拉西林/他唑巴坦对从囊性纤维化患儿中分离出的铜绿假单胞菌的微生物活性。
Diagn Microbiol Infect Dis. 2015 Sep;83(1):53-5. doi: 10.1016/j.diagmicrobio.2015.04.012. Epub 2015 May 1.
3
Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.头孢洛扎-他唑巴坦对近期广谱临床厌氧分离株的活性。
Antimicrob Agents Chemother. 2014;58(2):1218-23. doi: 10.1128/AAC.02253-13. Epub 2013 Nov 25.
4
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).对 2011-2012 年美国医院分离的具有不同耐药模式的肠杆菌科和铜绿假单胞菌进行的头孢洛扎他唑巴坦的抗菌活性测试。
Antimicrob Agents Chemother. 2013 Dec;57(12):6305-10. doi: 10.1128/AAC.01802-13. Epub 2013 Oct 7.
5
In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.在中性粒细胞减少症小鼠的大腿中，新型头孢菌素头孢洛扎烷与他唑巴坦联合和不联合使用时对铜绿假单胞菌和肠杆菌科的体内活性，包括具有超广谱β-内酰胺酶的菌株。
Antimicrob Agents Chemother. 2013 Apr;57(4):1577-82. doi: 10.1128/AAC.01590-12. Epub 2012 Dec 28.
6
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.耐多药、广泛耐药和全耐药细菌：获得性耐药的国际专家临时标准定义建议
Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27.
7
The changing microbial epidemiology in cystic fibrosis.囊性纤维化中微生物流行病学的变化。
Clin Microbiol Rev. 2010 Apr;23(2):299-323. doi: 10.1128/CMR.00068-09.
8
Microbiological and epidemiological features of clinical respiratory isolates of Burkholderia gladioli.唐菖蒲伯克霍尔德菌临床呼吸道分离株的微生物学和流行病学特征
J Clin Microbiol. 2009 May;47(5):1510-6. doi: 10.1128/JCM.02489-08. Epub 2009 Mar 18.
9
Development of a recA gene-based identification approach for the entire Burkholderia genus.基于recA基因的整个伯克霍尔德菌属鉴定方法的开发。
Appl Environ Microbiol. 2005 Jul;71(7):3917-27. doi: 10.1128/AEM.71.7.3917-3927.2005.
10
Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III.洋葱伯克霍尔德菌基因变种III流行病学研究中基因分型方法的比较评估
J Clin Microbiol. 2002 Sep;40(9):3300-7. doi: 10.1128/JCM.40.9.3300-3307.2002.
Zotero 插件